سعر ساكيوترند 100مجم (49/51مجم) 10 اقراص (غير متوافر) 2026

Sacubitril/valsartan 49/51 mg film-coated tablets, box of 10, by Neotrend (DBK Pharma), Egypt; listed as not yet available on the market.

• Reduce the risk of cardiovascular death and heart-failure hospitalisation in adults with chronic heart failure (benefit clearest with below-normal LVEF)Population: AdultsDailyMed (U.S. National Library of Medicine)
• Symptomatic heart failure with systemic left ventricular systolic dysfunction in children 1 year and olderPopulation: Children 1 year and olderDailyMed (U.S. National Library of Medicine)

• Most common (>=5%): hypotension, hyperkalaemia, cough, dizziness and renal failure.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component; history of angioedema with previous ACE inhibitor or ARB therapy; concomitant ACE inhibitor (allow 36 hours when switching); concomitant aliskiren in patients with diabetes.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - fetal toxicity: drugs acting on the renin-angiotensin system can injure or kill the developing fetus; discontinue as soon as pregnancy is detected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Angioedema (higher rate in Black patients; do not re-administer), symptomatic hypotension, worsening renal function and hyperkalaemia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• ACE inhibitorsContraindicated (angioedema risk); do not give within 36 hours of switching.DailyMed (U.S. National Library of Medicine)
• Aliskiren / other ARBsContraindicated with aliskiren in diabetes; avoid aliskiren if eGFR <60; avoid other ARBs (product contains valsartan).DailyMed (U.S. National Library of Medicine)
• Potassium-sparing diuretics, potassium supplements, potassium salt substitutesMay increase serum potassium.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: RAS-acting drugs in the 2nd and 3rd trimesters reduce fetal renal function and increase fetal/neonatal morbidity and death; discontinue when pregnancy is detected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No human data; present in rat milk; breastfeeding is not recommended during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Sacubitril: Prodrug whose active metabolite LBQ657 inhibits neprilysin, increasing natriuretic peptide levels (US Entresto label).
• Valsartan: Blocks angiotensin II at the AT1 receptor, inhibiting its vasoconstrictor and aldosterone-releasing effects (US Entresto label).